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Jennifer J. Wheler1*, Johnique T. Atkins1, Filip Janku1, Stacy L. Moulder2, Roman Yelensky3, Philip J. Stephens3
and Razelle Kurzrock4Abstract
Background: The presence of multiple molecular aberrations in patients with breast cancer may correlate with
worse outcomes.
Case Presentations: We performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-
negative, hormone therapy-refractory breast cancer, who achieved partial or complete responses when treated with
anastrozole and everolimus. Tumors were analyzed using a targeted next generation sequencing (NGS) assay in a Clinical
Laboratory Improvement Amendments laboratory. Genomic libraries were captured for 3,230 exons in 182 cancer-related
genes plus 37 introns from 14 genes often rearranged in cancer and sequenced to high coverage. Patients received
anastrozole (1 mg PO daily) and everolimus (5 or 10 mg PO daily). Thirty-two patients with breast cancer were treated on
study and 5 (16 %) achieved a partial or complete response. Primary breast tissue was available for NGS testing in three of the
responders (partial response with progression free survival of 11 and 14 months, respectively; complete response with progression
free survival of 9+ months). The following molecular aberrations were observed: PTEN loss by immunohistochemistry,
CCDN1 and FGFR1 amplifications, and PRKDC re-arrangement (NGS) (patient #1); PIK3CA and PIK3R1 mutations, and
CCDN1, FGFR1, MYC amplifications (patient #2); TP53 mutation, CCNE1, IRS2 and MCL1 amplifications (patient #3). Some
(but not all) of these aberrations converge on the PI3K/AKT/mTOR pathway, perhaps accounting for response.
Conclusions: Patients with estrogen receptor-positive breast cancer can achieve significant responses on a combination
of anastrozole and everolimus, even in the presence of multiple molecular aberrations. Further study of next generation
sequencing-profiled tumors for convergence and resistance pathways is warranted.
Keywords: Breast cancer, Genomic aberrations, Next generation sequencingBackground
Gene aberrations including, but not limited to, mutations,
amplifications and rearrangements drive tumor growth.
Aberrations are common in breast cancer in genes such as
HER2 (ERBB2), BRCA, PIK3CA,TP53, GATA3, PTEN and
others [1–6]. The presence of multiple gene abnormalities
may also serve as an indicator of genetic instability and
therefore of poor patient prognosis [7, 8].
Hormone therapy is the treatment of choice for estro-
gen (ER) and progesterone (PR)-positive breast cancer,
but acquired resistance is a significant challenge. The
PI3K/AKT/mTOR pathway becomes activated and uti-
lized by cancer cells to bypass the effects of endocrine* Correspondence: jjwheler@mdanderson.org
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unless otherwise stated.therapy [9–11]. While investigating the combination of
anastrozole (an aromatase inhibitor that blocks estrogen
production) and everolimus (an mTOR inhibitor), we
noted partial or complete responses (PR or CR) with
progression-free survival (PFS) of at least 9 months in
five patients with breast cancer of 32 treated [12]. We
performed next-generation sequencing (NGS) on three
of the responders with available tissue. In depth analysis
revealed that, despite their responses, their tumors
demonstrated multiple aberrations in genes including
CCND1, CCNE1, FGFR1, MYC, IRS2, MCL1, PIK3CA,
PIK3R1, PRKDC, and TP53. The implications of these
diverse aberrations for understanding response and
resistance are discussed.
Case Presentations
At the time of analysis, 32 patients with advanced breast
cancer were treated with anastrozole and everolimus,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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months [12]. In depth analysis was performed using
NGS on three responders with available tissue (number
of prior therapies = 2, 4, and 7, respectively, in the meta-
static setting) (Table 1).
Patient #1 is a 38-year old woman with ER-positive
(90 %), PR-positive (60 %), HER2-negative, invasive ductal
carcinoma diagnosed in August 2009. The patient was re-
ferred to the Clinical Center for Targeted Therapy at MD
Anderson Cancer Center in February 2011. Previous ther-
apies in the metastatic setting included: (1) paclitaxel; (2)
5-fluorouracil, doxorubicin, cyclophosphamide; (3) tam-
oxifen; and (4) capecitabine. Immunohistochemistry re-
vealed complete nuclear PTEN loss. NGS of left breast
tumor tissue dated August 2009 revealed amplifications in
CCDN1 and FGFR1 in addition to a rearrangement in
PRKDC.
The patient was treated with anastrozole 1 mg PO
daily and everolimus 5 mg PO daily beginning March
2011. She attained a PR (56 % decrease in liver metasta-
ses) (Fig. 1) and remained on study for 11 months.
Patient #2 is a 48-year old woman with ER-positive
(95 %), PR-positive (80 %), HER2- negative, invasive ductal
carcinoma diagnosed in September 2007. At that time,
metastatic disease was found in the pleura and bones. The
patient was referred to our clinic in March 2011. Previous
therapies in the metastatic setting included: (1) tamoxifen;Table 1 Clinical Characteristics and Responses of Super-Responders
Patient No. 1 2
Age at Treatment (years) 38 48
Date of Diagnosis August 2009 Se
Date of Biopsy August 2009 Se
Histology Ductal D
ER Status 90 % Positive 95
PR Status 60 % Positive 80
HER2/neu Status Negative (FISH) N
Prior Treatment in
Metastatic Setting
Paclitaxel (3 months) 5-fluorouracil,
doxorubicin, cyclophosphamide (1 month)
Tamoxifen (3 months) Capacitabine ( 3 months)
Ta
V
D
cy
Prior Treatment with
Aromatase Inhibitor in
Metastatic Setting
(Duration)
No N
Molecular alterations
(Please reference
Additional file 1: Table S1)
Progression Free
Survival (months)
11 14
Best Response (%) −56 % −
aUnknown duration of treatment
FISH Fluorescent in-situ hybridization, IHC Immunohistochemistry(2) paclitaxel with bevacizumab; (3) vinorelbine; (4) fulves-
trant; (5) ixabepilone; (6) docetaxel; and (7) docetaxel,
doxorubicin and cyclophosphamide. Immunohistochemis-
try showed PTEN to be present. NGS of malignant tissue
from the left breast dated September 2007 revealed muta-
tions in PIK3CA and PIK3R1 in addition to amplifications
in CCDN1, FGFR1 andMYC.
The patient was treated with anastrozole 1 mg PO
daily and everolimus 5 mg PO daily starting March
2011. She achieved a PR (38 % decrease in measureable
disease). After 14 months on study, she showed signs of
progression. At that time, a third agent, fulvestrant (an
estrogen receptor antagonist) was added as per protocol
for triple combination therapy. Five months later, she
continues on this triple-agent treatment.
Patient #3 is a 44-year old woman with ER-positive
(>95 %), PR-negative, HER2-negative, invasive ductal car-
cinoma diagnosed in September 2010. The patient was re-
ferred to our clinic in October 2011. Previous therapies in
the metastatic setting included: (1) tamoxifen with zole-
dronic acid and (2) letrozole (progression free survival =
4 months). Immunohistochemistry showed intact PTEN.
NGS of tissue from the primary left breast tumor at the
time of diagnosis revealed a mutation in TP53 and amplifi-
cations in CCNE1, IRS2 andMCL1.
The patient was treated with anastrozole 1 mg PO
daily and everolimus 10 mg PO daily. At the time ofTreated with Anastrozole and Everolimus
3
44
ptember 2007 September 2010
ptember 2007 August 2010
uctal Ductal
% Positive 95 % Positive
% Positive Negative
egative (FISH) Negative (IHC)
moxifen (2 months) Paclitaxel, bevacizumaba
inorelbinea Fulvestrant (3 months) Ixabepilonea
ocetaxel (9 months) Docetaxel, doxorubicin,
clophosphamide (3 months)
Tamoxifen, zoledronic
acid (6 months)
Letrozole (4 months)
o Yes (4 months)
9+
38 % −100 %
Fig. 1 Patient #1 CAT scans of the abdomen show a partial response (56 % decrease in hepatic disease) after 6 months of treatment. Patient
received treatment for 11 months before progressing
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achieved a CR noted on PET/CT (Fig. 2) (time on study =
9+ months).
We present an in-depth analysis of three patients with
advanced, refractory breast cancer who attained remarkable
responses despite the fact that their tumors harbored
multiple gene alterations (Additional file 1: Table S1). Of
interest, in each case, despite the complexity of aberrations
revealed by NGS, many of the molecular abnormalities can
be shown to converge, at least in part, on the PI3K/AKT/
mTOR axis, perhaps accounting for the responses. On the
other hand, some of the genes involved also modulate other
pathways, and this fact may explain why two of the patients
attained only partial responses, and eventually relapsed.
In patient #1, who had ER/PR-positive disease, ab-
normalities included: PTEN loss; CCDN1 and FGFR1
amplifications and a re-arrangement in PRKDC. Yet, sheFig. 2 Patient #3 PET scans show metastatic bone disease that attained a c
remained on treatment after 9 months at the time of this analysisachieved a durable PR on anastrozole and everolimus.
PTEN loss is known to activate the PI3K pathway [13],
which might easily explain the response to the mTOR
inhibitor everolimus. Of interest, however, the other ab-
errant genes detected in this patient’s tumor might also
affect this pathway. For instance, CCND1, also known as
BCL1, is down regulated by mTOR inhibition [14, 15].
FGFR1 encodes a tyrosine kinase receptor belonging to
fibroblast growth factor receptor (FGFR) family; this
gene is amplified in 9 to 15 % of breast cancers [16–18].
Activation of FGFR induces PI3K and AKT pathway ac-
tivity through recruitment and tyrosine phosphorylation
of the docking protein Gab [19]. Finally, PRKDC was
rearranged in patient #1. This gene is a member of the
PI3K family and encodes the catalytic subunit of the
DNA-dependent protein kinase (DNA-PK). It functions
with the Ku70/Ku80 heterodimer protein in DNA doubleomplete metabolic response after 4.5 months of treatment. Patient
Wheler et al. BMC Cancer  (2015) 15:442 Page 4 of 6strand break repair and recombination [20]. Overall,
though there were several different aberrations in this
patient, each has some impact on PI3K/AKT/mTOR
signaling. Yet, some of the aberrations (e.g., FGFR1) also
activate other signaling pathways such as MAP kinase
[21], which might explain why complete response was not
attained and/or the eventual progression that developed
after 11 months.
In patient #2, who also achieved a durable PR
(14 months) on anastrozole and everolimus, multiple ab-
errations were seen as well. NGS of malignant tissue re-
vealed mutations in PIK3CA and PIK3R1, in addition to
amplifications in CCDN1, FGFR1 and MYC. Responses
of patients with PIK3CA-mutant breast, gynecologic and
other tumors to mTOR inhibitors has been previously
reported [3, 22–26]. The crosstalk between CCND1 and
FGFR1 (both amplified in this patient) and the PI3K/AKT/
mTOR pathway has been discussed above.MYC encodes a
transcription factor with multiple functions,[27] including
interaction with the PI3K/AKT/mTOR axis as evidenced
by the observation that MYC-induced proliferation and
transformation require AKT-mediated phosphorylation of
FoxO proteins [28]. Of interest, both this patient and
patient #1 harbored FGFR1 aberrations and, as mentioned,
FGFR1 can activate both PI3K and MAPK signals, hence
potentially explaining both initial response to everolimus
(via PI3K activation) and eventual resistance (via MAPK).
MYC might also play a role in limiting the response of this
patient to less than a CR, since MYC regulates expression
of a broad array of genes via its functions as a transcription
factor, transcriptional repressor, and regulator of global
chromatin structure by means of recruitment of histone
acetyltransferases [29].
Patient #3, who attained a CR on therapy, demonstrated
a mutation in TP53 and amplifications in CCNE1, IRS2 and
MCL1. TP53 is a regulator of PTEN, which is in itself a
negative regulatory of PIK3CA [30]. CCNE1 degradation is
regulated by GSK-3β, which is directly phosphorylated by
AKT [31, 32]. Insulin receptor substrates (IRS) serve as
downstream messengers from activated cell surface recep-
tors to numerous signaling pathway cascades including
PI3K [33]. Finally, mTORC1 promotes survival in part
through translational control ofMCL-1 [34]. Previous stud-
ies have demonstrated up-regulation of the PI3K/AKT/
mTOR pathway as a mechanism of resistance to hormone
therapy [35–40], and clinical trials combining hormone
therapy with mTOR inhibitors have shown promise in
breast and endometrial cancers [41–43]. Further, the com-
bination of exemestane (an aromatase inhibitor) and evero-
limus was FDA approved for metastatic breast cancer.
Other possibilities for the response in this patient may be
the effect of anastrazole or the development of new
molecular alterations since the primary diagnosis as
molecular profiling was done on primary breast tissue.In our study of anastrozole and everolimus in hormone
receptor-positive breast cancers we observed salutary
activity in patients with multiple gene aberrations. Patient
#1 and Patient #2 demonstrated direct alterations in the
PI3K/AKT/mTOR pathway (PTEN loss and PIK3CA mu-
tation, respectively) in addition to multiple gene amplifica-
tions and additional rearrangements or mutations. It is
therefore plausible that these patients responded because
their tumors maintained dependence on or addiction
to the PI3K/AKT/mTOR axis despite the presence of
additional gene alterations. Recently, Hortobagyi et al. [25]
reported that patients treated on the Phase 2 BOLERO-2
study had a greater treatment effect if they had no or only
1 genetic alteration in PI3K or FGFR pathways or CCND1.
Some of the additional molecular alterations demonstrated
by NGS in our patients may however also modulate the
PI3K/AKT/mTOR axis, as noted above, explaining our
findings. Systems biology approaches that map convergence
pathways may therefore enhance treatment for patients [5,
6, 44, 45]. Alternatively, an eventual relapse (and in patients
#1 and #2, partial, rather than complete, response) could be
the result of the actions of the additional molecular alter-
ations. Of interest, at the time of progression, fulvestrant,
an estrogen receptor antagonist, was added to anastrozole
and everolimus in patient #2, with a 5+ month disease
stabilization. This strategy (adding an agent rather than
changing regimens) is consistent with observations in
patients with HER2-positive metastatic breast cancer that
continuation of trastuzumab beyond progression can be
beneficial [46] as well as our observations on resistance and
retreatment [47]. The mechanism is unclear but could
relate to residual sensitive tumor cells that co-exist with the
emerging resistant clone.
Methods
Patients
As part of a dose escalation study of the aromatase
inhibitor anastrozole and the mTOR inhibitor everolimus
(NCT01197170), we performed NGS on patients who had
attained PR or CR (and had a PFS of at least nine months)
and available tissue. NGS testing was not a part of
standard care, but was done retrospectively after re-
sponses were seen. Research involving human subjects
(including human material or human data) that is re-
ported in this study was conducted in accordance with
the guidelines of the MD Anderson Internal Review
Board, and patients signed informed consent for all
experimental therapeutic interventions and for the
deposit of NGS results.
Evaluation of HER2/neu amplification, estrogen and
progesterone receptor status
Under CLIA conditions, immunohistochemistry was used
to measure of HER2/neu, estrogen and progesterone
Wheler et al. BMC Cancer  (2015) 15:442 Page 5 of 6receptors. Estrogen and progesterone receptors were
assessed using antibody 6 F11 (Novocastra Laboratories,
Ltd., Newcastle Upon Tyne, UK). Alternatively, fluores-
cence in situ hybridization (FISH) was used to measure
the copy number of HER2/neu.
Next-generation sequencing
Molecular analysis using NGS was performed on arch-
ival formalin-fixed, paraffin-embedded tissue. Genomic
libraries were captured for 3230 exons in 182 cancer-
related genes plus 37 introns from 14 genes often rear-
ranged in cancer and sequenced to average median depth
of 734× with 99 % of bases covered >100× (Foundation
Medicine, Cambridge, MA, USA).
Evaluation of PTEN expression
PTEN expression was assessed using a Dako antibody
(Carpinteria, CA, USA) as previously published [49, 50].
Evaluation of response
Responses were assessed after three cycles (about
12 weeks) or earlier at the discretion of the treating
physician. All radiological tests were assessed by an MD
Anderson radiologist. In addition, results were reviewed
in a departmental tumor measurement clinic and by
the attending physician. RECIST criteria were used for
progressive disease (PD), stable disease (SD), partial and
complete responses (PR and CR).
Conclusions
In each of these “super-responders,” tumor tissue that
was derived from diagnosis was analyzed by NGS. It is
conceivable that the number of aberrations increased by
the time the patient was treated in our clinic, which was
between one and 3.5 years after diagnosis, especially
since each of these patients had received multiple inter-
vening therapies, and now had advanced metastatic
disease. Despite these limitations, NGS on tissue from
diagnosis was informative, and revealed abnormalities
that were actionable, similar to an earlier report by
Kalinsky et al. [48]. Optimizing future studies probably
requires fresh biopsies at the time of each relapse. How-
ever, in their absence, tumor tissue derived from an earlier
point in time still yields useful information. Our observa-
tions suggest that NGS can help unravel the mechanisms
of response and resistance, and warrants additional inves-
tigation as a clinical tool to optimize treatment.
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